CRVS · NASDAQ
Corvus Pharmaceuticals (CRVS) Stock Price & Fundamentals
Corvus Pharmaceuticals (CRVS) closed at $949.67 on Oct 9, 2026, down 1.11% from the previous close of $960.33.
Share price, past year
1Y +20.37%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $949.67 |
| Sep 30, 2026 | $974.19 |
| Aug 31, 2026 | $989.40 |
| Jul 31, 2026 | $918.48 |
| Jun 30, 2026 | $881.71 |
| May 29, 2026 | $876.09 |
| Apr 30, 2026 | $848.06 |
| Mar 31, 2026 | $841.60 |
| Feb 27, 2026 | $844.49 |
| Jan 30, 2026 | $837.96 |
| Dec 31, 2025 | $823.33 |
| Nov 28, 2025 | $793.55 |
| Oct 31, 2025 | $866.67 |
Key statistics
- Market cap
- $79.89B
- EPS (TTM)
- −$0.64
- Net income (TTM)
- −$54.13M
- Shares outstanding
- 84.1M
- 52-week range
- $788.98 – $1,006.63
Corvus Pharmaceuticals's market cap is $79.89B, based on a share price of $949.67 and 84.1M shares outstanding as of Jun 30, 2026.
Financials
Corvus Pharmaceuticals's SEC filings don't report revenue in the standard form Laurel reads, so its revenue history isn't shown yet.
Corvus Pharmaceuticals reported a net loss of $15.28M in fiscal 2025.
Company profile
- Name
- Corvus Pharmaceuticals, Inc.
- Ticker
- CRVS
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 901 Gateway Blvd, Third Floor, South San Francisco, CA 94080
- Incorporated in
- DE
- Fiscal year ends
- December
- SEC CIK
- 0001626971
Recent SEC filings
- Aug 6, 2026
- Aug 6, 2026
- Jul 22, 2026
- Jun 12, 2026
- May 14, 2026
- May 7, 2026
- May 7, 2026
- Apr 23, 2026
Frequently asked questions
What is Corvus Pharmaceuticals's stock price?
Corvus Pharmaceuticals (CRVS) closed at $949.67 on Oct 9, 2026, down 1.11% from the previous close of $960.33.
What is Corvus Pharmaceuticals's market cap?
Corvus Pharmaceuticals's market cap is $79.89B, based on a share price of $949.67 and 84.1M shares outstanding as of Jun 30, 2026.
Does Corvus Pharmaceuticals pay a dividend?
Corvus Pharmaceuticals's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Corvus Pharmaceuticals, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures